Innovation in personalized medicine for cancer therapy management
Rna Diagnostics is a cancer diagnostics company building a platform of predictive biomarkers to improve the lives of cancer patients. Founded in 2010, Rna Diagnostics’ platform technology is the RNA Disruption Assay™.
The RNA Disruption Assay™ (RDA™) will provide physicians with an evaluation of how individual patients are responding to cancer therapy. If the cancer drugs are likely to provide the patient with a benefit, the physician and patient can continue treatment with confidence. If the cancer drugs are not likely to benefit the patient, physicians may consider alternate treatments. For patients, this means avoiding harmful side effects and increasing the possibility of improved survival outcomes.
Rna Diagnostics is conducting a pivotal clinical trial in primary breast cancer called BREVITY. Rna Diagnostics also has collaborations in progress with researchers in Europe and North America in rectal, head and neck and metastatic breast cancer. The RNA Disruption Assay is available for clinical trial use from a state-of-the-art laboratory in Sudbury, Ontario, Canada.
RDA has the potential to substantially improve cancer treatment for patients while reducing costs for healthcare systems.

Read what Professor Daniele Generali, RDA Clinical Research Collaborator has to say about Rna Diagnostics
Professor Daniele Generali
“RDA represents a major advance in the management of breast cancer therapy. It offers the promise of real time monitoring of patient response to cancer treatment. RDA will allow us to make better informed treatment decisions that will improve the lives of our patients.”
Associate Professor in Medical Oncology
Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, Trieste, Italy
Meet the Rna Diagnostics Team
An experienced management team and world renowned clinical advisory board providing a Real Time cancer therapy guidance tool.
Rna Team
Clinical Advisors
Board of Directors
Rna Diagnostics’ Supporters
Supporters include:
- Georgian Angel Network
- Golden Triangle Angelnet
- Health Technology Exchange
- Northern Ontario Heritage Fund Corporation
Rna Diagnostics receives support from organizations and individuals that believe RDA will provide critical information to physicians, improve the lives of cancer patients while reducing healthcare costs.

Read what Nick Dipietro, Executive Director, Niagara Angel Network & Former President Of Patheon Inc. has to say about RDA
Nick Dipietro
“Rna Diagnostics’ RDA™ test will dramatically improve patient care and reduce health care costs. The underlying proprietary technology has the potential to create innovative products for healthcare systems worldwide. The experienced leadership team at Rna Diagnostics has the ability and drive to make this company a world success.”

Read what Dr. Maureen E. Trudeau has to say about RDA
Dr. Maureen E. Trudeau
“The RDA score could help us to predict which patients’ tumours will or will not respond to chemotherapy early in the course of treatment. This will allow a rapid change in treatment for those with unresponsive tumours.”
Chair of the Rna Diagnostics Clinical Advisory Board, Dr. Maureen E. Trudeau Professor of Medicine at the University of Toronto, Medical Oncologist at the Odette Cancer Centre, Sunnybrook Health Sciences Centre, and co-chair of the breast cancer disease site group of Cancer Care Ontario.
For more information about investing in Rna Diagnostics, please contact:
John Connolly -Executive Vice President Corporate Development
416-985-4361 • jconnolly@rnadiagnostics.com
The Chemo Response Company